Homology Medicines, Inc. (0T6G.L)
USD 1.94
(-2.52%)
USD 1.94
(-2.52%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -7.22 Million USD | -6402.13% |
| 2022 | 609 Thousand USD | -97.51% |
| 2021 | 24.42 Million USD | 125.0% |
| 2020 | -97.69 Million USD | -11.35% |
| 2019 | -87.73 Million USD | -105.82% |
| 2018 | -42.62 Million USD | -6129.92% |
| 2017 | -684.21 Thousand USD | -185.33% |
| 2016 | -239.79 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -123 Thousand USD | 99.47% |
| 2024 Q2 | -13.41 Million USD | -10803.25% |
| 2023 Q3 | -136 Thousand USD | 35.24% |
| 2023 Q4 | -23 Million USD | -16812.5% |
| 2023 Q1 | 215 Thousand USD | 27.22% |
| 2023 FY | 578 Thousand USD | -5.09% |
| 2023 Q2 | -210 Thousand USD | -197.67% |
| 2022 Q1 | 257 Thousand USD | 116.13% |
| 2022 Q4 | 169 Thousand USD | 1.2% |
| 2022 Q2 | 16 Thousand USD | -93.77% |
| 2022 Q3 | 167 Thousand USD | 943.75% |
| 2022 FY | 609 Thousand USD | -97.51% |
| 2021 Q2 | -21.51 Million USD | -384.9% |
| 2021 FY | 24.42 Million USD | 125.0% |
| 2021 Q1 | 7.55 Million USD | 133.99% |
| 2021 Q4 | -1.59 Million USD | 92.86% |
| 2021 Q3 | -22.31 Million USD | -3.72% |
| 2020 Q4 | -22.21 Million USD | -11.91% |
| 2020 FY | -97.69 Million USD | -11.35% |
| 2020 Q2 | -26.9 Million USD | 6.33% |
| 2020 Q1 | -28.72 Million USD | -45.21% |
| 2020 Q3 | -19.85 Million USD | 26.22% |
| 2019 Q3 | -25.25 Million USD | -12.55% |
| 2019 Q1 | -20.26 Million USD | -34.35% |
| 2019 FY | -87.73 Million USD | -105.82% |
| 2019 Q4 | -19.77 Million USD | 21.67% |
| 2019 Q2 | -22.43 Million USD | -10.7% |
| 2018 Q2 | -8.89 Million USD | -29.51% |
| 2018 Q4 | -15.08 Million USD | -27.93% |
| 2018 FY | -42.62 Million USD | -6129.92% |
| 2018 Q1 | -6.86 Million USD | 28.28% |
| 2018 Q3 | -11.79 Million USD | -32.57% |
| 2017 Q1 | -2.79 Million USD | 0.0% |
| 2017 FY | -684.21 Thousand USD | -185.33% |
| 2017 Q3 | -4.94 Million USD | -21.95% |
| 2017 Q4 | -9.57 Million USD | -93.59% |
| 2017 Q2 | -4.05 Million USD | -44.91% |
| 2016 FY | -239.79 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.38% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 91.517% |
| Myriad Genetics, Inc. | 476.4 Million USD | 101.517% |
| Evolus, Inc. | 140.52 Million USD | 105.144% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.929% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.209% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 141.74% |
| uniQure N.V. | 2.21 Million USD | 426.366% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -2209.585% |
| bluebird bio, Inc. | -4.03 Million USD | -79.38% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 2493.709% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.476% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 101.519% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 101.997% |
| Dynavax Technologies Corporation | 182.11 Million USD | 103.969% |
| Editas Medicine, Inc. | -99.52 Million USD | 92.737% |
| FibroGen, Inc. | 128.9 Million USD | 105.608% |
| Geron Corporation | -123.5 Million USD | 94.147% |
| Blueprint Medicines Corporation | 236.58 Million USD | 103.056% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.138% |
| Illumina, Inc. | 2.74 Billion USD | 100.263% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 24.43% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -2285.809% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.391% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 148.864% |
| Adicet Bio, Inc. | -6.09 Million USD | -18.547% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.661% |
| Insmed Incorporated | 239.63 Million USD | 103.017% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 98.187% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.333% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 63.303% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 101.38% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.027% |
| Waters Corporation | 1.76 Billion USD | 100.41% |
| Zoetis Inc. | 5.83 Billion USD | 100.124% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.047% |
| Biogen Inc. | 7.3 Billion USD | 100.099% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 84.051% |
| Nektar Therapeutics | 53.47 Million USD | 113.518% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -2375.685% |
| Perrigo Company plc | 1.68 Billion USD | 100.43% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 102.956% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 171.988% |
| Verastem, Inc. | -62 Thousand USD | -11559.677% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.084% |
| Imunon, Inc. | -720 Thousand USD | -904.021% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 76.806% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 109.894% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.064% |
| OPKO Health, Inc. | 318.12 Million USD | 102.272% |
| Exelixis, Inc. | 1.75 Billion USD | 100.411% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 101.135% |
| TG Therapeutics, Inc. | 219.1 Million USD | 103.299% |
| Incyte Corporation | 3.44 Billion USD | 100.21% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 102.102% |